strong end year growth stori
track guid check box
core growth softer margin limit ep
revenu our/street core growth
organ basi ex-abaxi adjust sell day headwind
fx headwind beat led companion anim strength despit
tough comp livestock result mute still ahead expect due
stronger expect fx headwind neg mix write-off older inventori
margin came light gm opm adj ep ahead
street benefit non-op item first look detail
driver new product continu perform well
segment/geographi result solidli line ahead expect
robust perform dermatolog portfolio yoy simparica
yoy steadi out-performance product even rel
aggress estim reaffirm confid continu runway believ
sale dermatolog reason target particularli ou
ramp cytopoint still earli stage apoquel expect launch china
year see strong return dtc campaign us abaxi contribut also
line prior expect integr proceed well
expect step-funct chang perform near term given
underli market dynam space
thought well ahead lower expect
see initi guid line ahead key metric organ sale
growth plu growth abaxi deal nearli oper margin
expans full-year basi adj ep management notabl lower
expect earlier januari link guid still leav us feel posit
runway beyond particularli given increment margin
improv cog sg upsid potenti captur
current estim ie share buyback adjust model see
sale adj ep reiter buy rate rais po po
price-to-earnings vs previous line compani recent valuat
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth
po base approxim ep estim back
dcf assum wacc termin growth rate in-lin
current multipl well averag multipl recent year
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
downsid risk price object competit select market weaker demand
anim health product regulatori issu macroeconom condit currenc risk
headwind relat regul antibiot use anim feed addit
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
